Aurobindo Pharma

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Aurobindo Pharma" – news · newspapers · books · scholar · JSTOR (February 2017) (Learn how and when to remove this message)

Aurobindo Pharma Limited

Company type	Public
Traded as	NSE: AUROPHARMA BSE: 524804
Industry	Pharmaceuticals
Founded	1986
Founders	V. Ramprasad Reddy[1] K. Nityananda Reddy[1]
Headquarters	Hyderabad, Telangana, India
Products	Pharmaceuticals generic drugs over-the-counter drugs vaccines diagnostics contact lenses animal health[2]
Revenue	₹29,002 crore (US$3.5 billion) (FY24)[3]
Operating income	₹5,843 crore (US$700 million) (FY24)[3]
Net income	₹3,173 crore (US$380 million) (FY24)[3]
Total assets	₹28,926 crore (US$3.5 billion) (2020)[4]
Total equity	₹16,751 crore (US$2.0 billion) (2020)[4]
Number of employees	23,000[5] (2020)
Website	www.aurobindo.com

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.^[6] The company markets these products in over 125 countries.^[6] Its marketing partners include AstraZeneca^[7] and Pfizer.^[8]